MedTrace Logo

P4 Peptide in Community Acquired Pneumonia

NCT03497962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2025-03-19

No results posted yet for this study

Summary

The investigators' aim is to find out whether immune cells from patients with a severe chest infection will react ex vivo to a new immunomodulating peptide, P4 as part of augmented passive immunotherapy

The investigators know that P4 treatment can successfully improve the efficiency of specialized immune cells responsible for killing bacteria. The investigators also know that P4 treatment is effective in healthy human volunteers but wish to extend this observation to patients that have infection, as immune cells may react differently in these patients. If this study is successful, the investigators hope to be moving closer to a new treatment against severe bacterial infections.

The investigators plan to recruit patients admitted to the Intensive Care Unit (ICU) and healthy volunteers, using carefully established inclusion and exclusions criteria with severe community acquired pneumonia (CAP) and obtain both blood and (if clinically feasible), a bronchoscopy BAL sample (washing of lung tissue).

Conditions

Interventions

PROCEDURE

Venepuncture

Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.

PROCEDURE

Bronchoscopy

Broncho-alveolar lavage to obtain alveolar macrophages

Sponsors & Collaborators

  • Liverpool School of Tropical Medicine

    collaborator OTHER

  • Liverpool University Hospitals NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Stephen B Gordon, Professor · Royal Liverpool University Hospital/ Liverpool School of Tropical Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497962 on ClinicalTrials.gov